153Sm: its use in multiple myeloma and report of a clinical experience.
BACKGROUND
In the past years the bone seeking radiopharmaceutical samarium lexidronam ((153)Sm-EDTMP) has been increasingly used alone or in conjunction with chemotherapy and/or bisphosphonates for the treatment of painful bone metastasis.


OBJECTIVE
Its use has been explored in different solid tumours. In this report we explore its interesting characteristics and describe our experience in multiple myeloma (MM).


METHODS
(153)Sm-EDTMP has an affinity for bone and concentrates in areas of bone turnover. It decays as a therapeutic beta-emission and at the same time as gamma-photon that can be used for tracking its concentration with bone scan imaging. Ten patients with symptomatic MM were treated to achieve pain control.


RESULTS
Encouraging results were obtained in MM patients. The use of this radioisotope could be largely improved.
Abruzzese
Elisabetta
E
Tor Vergata University, S. Eugenio Hospital, Hematology, P.le dell'Umanesimo 10, 00144 Rome, Italy. elisabetta.abruzzese@uniroma2.it
Iuliano
Francesco
F
Trawinska
Malgorzata Monika
MM
Di Maio
Massimo
M
D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007554:Isotopes; D009101:Multiple Myeloma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000532:radiotherapy; D009942:Organometallic Compounds / Q000737:chemistry / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000737:chemistry / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy / Q000532:radiotherapy; D011859:Radiography; D012493:Samarium / Q000627:therapeutic use*
D004164:Diphosphonates; D007554:Isotopes; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D012493:Samarium; C061972:samarium Sm-153 lexidronam